Volume 18, Number 2—February 2012
Clonal Spread of Mycoplasma pneumoniae in Primary School, Bordeaux, France
To the Editor: Mycoplasma pneumoniae is responsible for ≈20% of all cases of community-acquired pneumonia. The most common form of the infection is tracheobronchitis, for which an etiologic diagnosis is seldom reached (1). Although tracheobronchitis is often mild, the infection is disruptive, with the cough lasting several weeks, and consumes substantial resources (2). M. pneumoniae infections occur endemically and epidemically worldwide, especially in children and young adults (1). In 2010, an increased incidence was reported from Denmark (3), England and Wales (4), and Israel (5). Several outbreaks have been reported in closed or semiclosed settings, as indicated on the basis of similar clinical symptoms, chest radiograph results, and detection of the bacteria (1).
Previous M. pneumoniae typing methods were based on the analysis of the gene encoding the cytadhesin P1 (MPN141) or the gene MPN528a (6). These methods only enabled the separation of isolates into 2 types and a few variants; therefore, clinical isolates were previously poorly differentiated. We recently developed a multilocus variable-number tandem repeat analysis (MLVA), based on the study of the whole genome, that can differentiate >26 distinct variable-number tandem repeat types (7). We report the use of this MLVA typing method to show evidence of a clonal spread of a unique strain of M. pneumoniae among children in a French primary school and their household contacts.
In January 2011, 6 children (4–9 years of age), who attended the same primary public school in Bordeaux, France, reported fever, pharyngitis, rhinorrhea, and dry cough that later became mucoid. One of the children was admitted to the pediatric ward of the University Hospital of Bordeaux, and atypical pneumonia was confirmed by radiologic testing. A diagnosis of tracheobronchitis was confirmed by general practitioners for the 5 other children. Three of the children were administered β-lactam antimicrobial drugs that did not modify the course of the illness. An additional child (4 years of age), a first cousin of one of the 6 case-patients, also received a diagnosis of tracheobronchitis after repeated contact with his cousin.
Throat swab or blood samples were obtained from the 7 children, and throat swab samples were obtained from the household members of 4 of their families. DNA was extracted from throat specimens, and a TaqMan real-time PCR was performed to detect M. pneumoniae as described (8). MLVA typing was performed on the same DNA extracts, according to the method of Dégrange et al. (7). M. pneumoniae–specific IgM and IgG in serum specimens were assessed by ELISA. PCR was used to detect Bordetella pertussis, B. parapertussis, Chlamydia pneumoniae, Streptococcus pneumoniae, and viruses commonly responsible for respiratory tract infections. In France, 10% of M. pneumoniae isolates are resistant to macrolides (9); thus, we used real-time PCR and melting curve analysis to detect macrolide resistance–associated mutations in the 23S rRNA gene (9).
The 7 children were confirmed to be positive for M. pneumoniae infection by PCR or by the presence of M. pneumoniae–specific IgM (Figure). No other respiratory tract pathogens were found. In all cases, MLVA determined the strain type to be 34572, also called MLVA type J (7); this finding suggests clonal spread of a specific M. pneumoniae strain. No macrolide resistance–associated mutation was found in the 23S rRNA gene. All children were treated with roxithromycin or clarithromycin and rapidly recovered, although PCR results remained positive for up to 6 weeks in subsequent throat samples. This length of persistence is in accordance with a previous study showing that the median time for carriage of M. pneumoniae DNA was 7 weeks after disease onset and that adequate treatment did not shorten this period (10).
M. pneumoniae DNA was also found in throat swab specimens of 3 household contacts (2 adults and a 1-year-old child) in 3 separate families (Figure). The MLVA type was determined in 1 contact; it also was MLVA type J, suggesting that carriage in this contact was related to spread of the same clone. Of interest, none of these 3 household members had respiratory symptoms. Nilsson et al. (10) also reported a high frequency of M. pneumoniae DNA carriage in household contacts; however, in contrast to contacts in our study, all of the household contacts in the study by Nilsson et al. had ongoing or recent respiratory tract symptoms.
In summary, we report an outbreak of M. pneumoniae infections confirmed by MLVA, a discriminatory typing method. MLVA typing revealed the clonal spread of a single M. pneumoniae type J strain in children attending the same primary school and in their household contacts. The cases we identified may represent only a small proportion of the actual cases, which were likely underestimated due to mild symptoms, poor knowledge of M. pneumoniae infections by general practitioners, and lack of PCR availability. We showed that MLVA typing of M. pneumoniae can be used to detect clonal spread and outbreaks. This approach might also be useful for studying the worldwide emergence of M. pneumoniae macrolide resistance and for finding resistant clones with the potential for spreading.
We thank Florence Bernard for technical assistance.
This study was supported by internal funding.
- Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol Rev. 2008;32:956–73.
- Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev. 2004;17:697–728.
- Rasmussen JN, Voldstedlund M, Andersen RL, Ellermann-Eriksen S, Jensen TG, Johansen HK, Increased incidence of Mycoplasma pneumoniae infections detected by laboratory-based surveillance in Denmark in 2010. Euro Surveill. 2010;15:pii:19708.
- Chalker V, Stocki T, Mentasti M, Fleming D, Harrison TG. Increased incidence of Mycoplasma pneumoniae infection in England and Wales in 2010: multilocus variable number tandem repeat analysis typing and macrolide susceptibility. Euro Surveill. 2011;16:pii:19865.
- Averbuch D, Hidalgo-Grass C, Moses AE, Engelhard D, Nir-Paz R. Macrolide resistance in Mycoplasma pneumoniae, Israel, 2010. Emerg Infect Dis. 2011;17:1079–82.
- Spuesens EB, Hoogenboezem T, Sluijter M, Hartwig NG, van Rossum AM, Vink C. Macrolide resistance determination and molecular typing of Mycoplasma pneumoniae by pyrosequencing. J Microbiol Methods. 2010;82:214–22.
- Dégrange S, Cazanave C, Charron A, Renaudin H, Bebear C, Bebear CM. Development of multiple-locus variable-number tandem-repeat analysis for molecular typing of Mycoplasma pneumoniae. J Clin Microbiol. 2009;47:914–23.
- Touati A, Benard A, Ben Hassen A, Bebear CM, Pereyre S. Evaluation of five commercial real-time PCR assays for the detection of Mycoplasma pneumoniae in respiratory tract specimens. J Clin Microbiol. 2009;47:2269–71.
- Peuchant O, Menard A, Renaudin H, Morozumi M, Ubukata K, Bebear CM, Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother. 2009;64:52–8.
- Nilsson AC, Bjorkman P, Persson K. Polymerase chain reaction is superior to serology for the diagnosis of acute Mycoplasma pneumoniae infection and reveals a high rate of persistent infection. BMC Microbiol. 2008;8:93.
Suggested citation for this article: Pereyre S, Renaudin H, Charron A, Bébéar C. Clonal spread of Mycoplasma pneumoniae in primary school, Bordeaux, France [letter]. Emerg Infect Dis [serial on the Internet]. 2012 Feb [date cited]. http://dx.doi.org/10.3201/eid1802.111379
Please use the form below to submit correspondence to the authors or contact them at the following address:
Sabine Pereyre, USC Infections Humaines à Mycoplasmes et Chlamydia, Université Bordeaux Segalen, Bât 2B, 146 Rue Léo Saignat, 33076 Bordeaux, France
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: January 18, 2012
- Page last updated: January 18, 2012
- Page last reviewed: January 18, 2012
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)